07:00 , Aug 12, 2013 |  BC Week In Review  |  Clinical News

Lakewood-Amedex preclinical data

In vitro, Nu-3 led to a rapid >5 log reduction in bacterial counts of New Delhi metallo-beta-lactamase 1 (NDM-1)-positive Klebsiella pneumonia and Escherichia coli, with a 100% reduction in bacterial counts after a 15 minute...
08:00 , Dec 19, 2011 |  BioCentury  |  Regulation

Europe speeds away

The European Commission's new action plan to combat antimicrobial resistance could further widen the regulatory gap between the U.S. and Europe, which is already at the point where some physicians worry companies will no longer...
07:00 , May 16, 2011 |  BC Week In Review  |  Clinical News

Basilea preclinical data

In vitro, 4 mg/L BAL30072 was active against 60% of 78 isolates of Gram-negative bacteria containing New Delhi metallo-beta-lactamase 1 (NDM-1) vs. <10% for aztreonam, ceftazidime and meropenem. Additionally, BAL30072 plus meropenem was active against...